Nektar Therapeutics (NASDAQ:NKTR) Shares Acquired by Barclays PLC

Barclays PLC increased its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR) by 96.1% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 358,294 shares of the biopharmaceutical company’s stock after purchasing an additional 175,596 shares during the quarter. Barclays PLC’s holdings in Nektar Therapeutics were worth $466,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Samlyn Capital LLC acquired a new position in Nektar Therapeutics during the second quarter valued at approximately $11,728,000. Eventide Asset Management LLC raised its stake in shares of Nektar Therapeutics by 24.8% in the 3rd quarter. Eventide Asset Management LLC now owns 9,400,000 shares of the biopharmaceutical company’s stock valued at $12,220,000 after acquiring an additional 1,870,904 shares during the period. Millennium Management LLC lifted its holdings in shares of Nektar Therapeutics by 56.1% during the 2nd quarter. Millennium Management LLC now owns 4,659,469 shares of the biopharmaceutical company’s stock valued at $5,778,000 after acquiring an additional 1,674,924 shares in the last quarter. Nantahala Capital Management LLC boosted its position in Nektar Therapeutics by 66.0% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,110,000 shares of the biopharmaceutical company’s stock worth $5,096,000 after purchasing an additional 1,634,046 shares during the period. Finally, State Street Corp increased its holdings in Nektar Therapeutics by 11.9% in the 3rd quarter. State Street Corp now owns 3,345,733 shares of the biopharmaceutical company’s stock valued at $4,349,000 after purchasing an additional 355,759 shares in the last quarter. Institutional investors and hedge funds own 75.88% of the company’s stock.

Nektar Therapeutics Stock Performance

NASDAQ:NKTR opened at $0.96 on Friday. The stock has a market cap of $177.26 million, a price-to-earnings ratio of -1.14 and a beta of 0.57. Nektar Therapeutics has a one year low of $0.48 and a one year high of $1.93. The business’s 50-day simple moving average is $1.10 and its 200 day simple moving average is $1.21.

Insiders Place Their Bets

In other Nektar Therapeutics news, CEO Howard W. Robin sold 46,995 shares of the stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $1.01, for a total transaction of $47,464.95. Following the transaction, the chief executive officer now directly owns 1,195,710 shares in the company, valued at $1,207,667.10. This represents a 3.78 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jonathan Zalevsky sold 51,115 shares of the firm’s stock in a transaction on Thursday, December 19th. The stock was sold at an average price of $0.94, for a total transaction of $48,048.10. Following the transaction, the insider now directly owns 326,904 shares of the company’s stock, valued at approximately $307,289.76. This represents a 13.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 155,575 shares of company stock worth $149,878 in the last three months. 3.71% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have commented on NKTR shares. BTIG Research restated a “buy” rating and set a $4.00 price objective on shares of Nektar Therapeutics in a research note on Monday, September 30th. HC Wainwright began coverage on Nektar Therapeutics in a research report on Tuesday, December 10th. They set a “buy” rating and a $6.50 price target on the stock. Finally, Piper Sandler started coverage on shares of Nektar Therapeutics in a research report on Monday, November 4th. They issued an “overweight” rating and a $7.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, Nektar Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $4.10.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.